PRPO Precipio, Inc.
$18.91▼ -3.03%
Healthcare
Other
Volume 19.7K
Avg Volume (10D) 45.5K
Key Metrics & Fundamentals
Market Cap
$33.85M
P/E Ratio
–
Div Yield
0.00%
52W Range
18.50 - 33.63
% vs 50 MA
-24.66%
% vs 200 MA
-24.63%
RSI-14
23.8
MACD Histogram
-0.2600
Beta (1Y vs SPY)
0.42
Free Cash Flow
$528,000
Gross Rev
$7.02M
Gross Profit
$3.14M
EBITDA
-$130,000
COGS
$3.89M
Operating Exp
$3.74M
Operating Income
-$599,000
EBIT
-$599,000
Pretax Income
-$219,000
Net Income
-$219,000
EPS (Diluted)
-0.12
Price & Volume History
Loading chart…
Recent News
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
Zacks · Sep 22, 2026 1:16 PM ET
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio
Zacks · Sep 11, 2026 5:20 AM ET
Top Research Reports for Goldman Sachs, RTX & Abbott
Zacks · Sep 10, 2026 4:12 PM ET
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Zacks · Aug 24, 2026 12:37 PM ET
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
Zacks · Aug 21, 2026 11:31 AM ET
Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...
GuruFocus.com · Aug 20, 2026 11:02 PM ET
Precipio, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 15, 2026 8:30 AM ET
Precipio Announces Q2-2026 Financial Results
GlobeNewswire · Aug 14, 2026 4:00 PM ET
Precipio Announces Q2-2026 Shareholder Update Call
GlobeNewswire · Jul 31, 2026 4:00 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See PRPO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.